Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2018

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Histiocytosis; Langerhans cell histiocytosis; Lymphoma; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Pediatric MATCH
  • Most Recent Events

    • 24 Sep 2018 According to an Epizyme media release, the U.S. FDA has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. The company is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of its Phase 2 non-Hodgkin lymphoma trial.
    • 24 Sep 2018 Status changed from suspended to recruiting, according to an Epizyme media release.
    • 08 May 2018 According to an Epizyme media release, French National Agency for Medicines and Health Products Safety (ANSM) has put this trial on hold in first week of May 2018. The company is working with the regulatory authorities to resume enrollment in clinical trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top